Clinical Trials on Hepatic Disease

Total 377302 results

H. Lundbeck A/S

Completed

Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects

Heptic Impairment

Germany
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Peking University People's Hospital

Completed

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Normal Hepatic Function | Impaired Hepatic Function

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

Severe Hepatic Impairment | Normal Hepatic Function

Bulgaria
Pfizer

Completed

Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction

Mild Hepatic Dysfunction | Moderate Hepatic Dysfunction

South Africa
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Healthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

Normal Hepatic Function | Impaired Hepatic Function

United States
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDE225..

Normal Hepatic Function | Impaired Hepatic Function

Belgium, Germany, Israel, Bulgaria, United States
Assistance Publique - Hôpitaux de Paris

Unknown

Patients' Outcome With Severe or Fulminant Hepatic Insufficiency, Hospitalized in the Public Hospitals of Paris (DEVINHEF)

Fulminating Hepatic Failure

France
Eisai Inc.

Completed

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Hepatic Impairment | Hepatic Function

United States
Hong Kong Children's Hospital

Recruiting

Ultrasound Measurements of Hepatic Vasculatures and Hepatic Doppler Assessment of Healthy Children

Portal Vein | Hepatic Veins | Hepatic Artery | Liver Circulation

Hong Kong
Agios Pharmaceuticals, Inc.

Completed

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Moderate Hepatic Impairment

United States
Vital Therapies, Inc.

Completed

Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure

Fulminant Hepatic Failure

United States
Vital Therapies, Inc.

Withdrawn

Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF) (ELAD)

Fulminant Hepatic Failure

United States
Bausch Health Americas, Inc.

Terminated

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Severe Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Hepatic Impairment | Normal Hepatic Function

United States
Cardiox Corporation

Terminated

Liver Function Assessment - Feasibility and Dosing Study

Hepatic Failure
Genfit

Completed

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Liver Diseases | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
Merck Sharp & Dohme LLC

Completed

Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)

Moderate Hepatic Impairment

United States
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
Takeda

Completed

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Severe Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

Hepatic Failure

United States
Daiichi Sankyo, Inc.

Completed

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Hepatic Impairment | Moderate Impaired Hepatic Function

United States
Mitsubishi Tanabe Pharma Corporation

Completed

PK Study in Subjects With Severe Hepatic Impairment (MCI-186-E05 HP)

Healthy | Severe Hepatic Impairment

Czechia, Hungary, Slovakia
KBP Biosciences
Covance

Completed

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Healthy | Moderate Hepatic Impairment

United States
Centre Hospitalier Universitaire de Nice

Completed

Pyrophosphate Homeostasis and Hepatic Expression of ABCC6.Pyro-TH (Pyro-TH)

Hepatic Failure

France
Rennes University Hospital

Completed

Comparison of the Variability of Hepatic Load Quantification in Iron and Fat Estimated by MRI at 1.5 and 3 Tesla (HEMOCOMPARE)

Iron Hepatic Overload | Fat Hepatic Overload

France
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Hepatic Impairment

United States
Tibotec BVBA

Completed

A Study of TMC207 in Patients With Moderately Impaired Hepatic Function

Moderate Hepatic Impairment
Pfizer
Medivation, Inc.

Completed

Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function

Hepatic Failure

United States
Jinnah Postgraduate Medical Centre

Not yet recruiting

Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy

Hepatic Encephalopathy Stage 2 | Hepatic Encephalopathy Stage 3 | Hepatic Encephalopathy Stage 4

Pakistan
The University of Texas Medical Branch, Galveston

Terminated

Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure

Acute and Chronic Hepatic Failure With Developing Coma

United States
BeiGene

Completed

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency & Healthy Subjects

United States
National Taiwan University Hospital

Unknown

Oxidative Stress and Microcirculation in Patient With Hepatic Failure Undergoing Liver Support Treatment

Liver Failure | Critical Care

Taiwan
Rigshospitalet, Denmark

Completed

Cerebral Microdialysis in Patients With Fulminant Hepatic Failure

Fulminant Hepatic Failure

Denmark
AdventHealth

Completed

Endoscopic Ultrasound Guided Liver Biopsy

Hepatic Cancer | Hepatic Carcinoma | Hepatic Neoplasm

United States
Pfizer

Completed

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

Healthy, Hepatic Insufficiency

United States
Taisho Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment

Patients With Mild or Moderate Hepatic Impairment

Japan
Acerta Pharma BV
AstraZeneca

Completed

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Hepatic Insufficiency | Healthy Subjects | Hepatic Impairment

United States
Fuzhou General Hospital

Unknown

The Plasma Diafiltration Therapy of Hepatic Failure

Hepatic Failure | Plasma Exchange

China
Assistance Publique - Hôpitaux de Paris

Completed

The MARS® Albumin Dialysis System in Patients With Fulminant and Subfulminant Hepatic Failure

Hepatitis

France
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Healthy Subjects | Pharmacokinetics | Mild and Moderate Hepatic Impairment

Slovakia
Merck Sharp & Dohme LLC

Completed

A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)

Chronic Hepatic Impairment
University Hospital, Strasbourg, France

Recruiting

Hydrodissection of the Hepatoduodenal Ligament (Duodenal)

Hepatic Lesions

France
Rennes University Hospital

Completed

Pharmacogenetic Study of Tacrolimus in Hepatic Transplant (CYPTAC'H)

Hepatic Transplantation

France
Maastricht University

Completed

Liver Glycogen Dynamics (LGD)

Hepatic Glycogen

Netherlands
Shire

Completed

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

Hepatic Impairment

United States
University of Michigan Rogel Cancer Center

Completed

Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation (IC-Green)

Hepatic Irradiation

United States

3

Subscribe